Details of the Drug

General Information of Drug (ID: DM6KZMG)

Drug Name
Ozenoxacin
Synonyms T-3912; GF-001001-00; Non-fluorinated quinolone (Gram positive bacterial infection), Ferrer
Indication
Disease Entry ICD 11 Status REF
Impetigo 1B72 Approved [1]
Bacterial infection 1A00-1C4Z Phase 3 [2]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 363.4
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Metabolism
The drug is not metabolised []
Chemical Identifiers
Formula
C21H21N3O3
IUPAC Name
1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
InChI
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
InChIKey
XPIJWUTXQAGSLK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
9863827
ChEBI ID
CHEBI:136050
CAS Number
245765-41-7
DrugBank ID
DB12924
TTD ID
D0X1HE
ACDINA ID
D01312
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Modulator [3]
DNA replication (DNA repli) TTABD5E NOUNIPROTAC Inhibitor [1]
Staphylococcus DNA gyrase A (Stap-coc gyrA) TTRVWAT GYRA_STAAU Inhibitor [1]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzoic acid E00009 243 Antimicrobial preservative
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Stearyl alcohol E00172 8221 Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Water E00035 962 Solvent
Octyldodecanol E00269 21414 Emollient; Emulsifying agent; Lubricant; Solvent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ozenoxacin 10 mg cream 10 mg Cream Topical
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 ClinicalTrials.gov (NCT02090764) Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo. U.S. National Institutes of Health.
3 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.